Free Trial

Roanna Ruiz Analyst Performance

Analyst at Leerink Partners

Roanna Ruiz is a stock analyst at Leerink Partners in the medical sector, covering 9 publicly traded companies. Over the past year, Roanna Ruiz has issued 8 stock ratings, including buy and hold recommendations. While full access to Roanna Ruiz's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Roanna Ruiz's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 3 Years
Buy Recommendations
69.23% 9 Buy Ratings
Companies Covered
9 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy69.2%9 ratings
Hold30.8%4 ratings
Sell0.0%0 ratings

Out of 13 total stock ratings issued by Roanna Ruiz at Leerink Partners, the majority (69.2%) have been Buy recommendations, followed by 30.8% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
88.9% of companies on NASDAQ
8 companies
NYSE
11.1% of companies on NYSE
1 company

Roanna Ruiz, an analyst at Leerink Partners, currently covers 9 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
9 companies
100.0%

Roanna Ruiz of Leerink Partners specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
44.4%
MED - DRUGS
3 companies
33.3%
PHARMACEUTICAL PREPARATIONS
2 companies
22.2%

Roanna Ruiz's Ratings History at Leerink Partners

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
8/19/2025Boost Price Target$7.59$9.00Outperform
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4/28/2025Initiated Coverage$2.38$7.00Outperform
CorMedix Inc stock logo
CRMD
CorMedix
3/7/2025Initiated Coverage$9.49$18.00Outperform
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
3/7/2025Boost Price Target$4.19$6.00Outperform
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
3/4/2025Reiterated Rating$0.32$1.00Market Perform
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
1/13/2025Boost Price Target$10.71$20.00Outperform
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
1/13/2025Boost Price Target$11.97$27.00Outperform
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
10/18/2024Set Price Target$2.04$6.00Outperform